This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effective treatment of ureteral disorders: A Synthesis of Findings from 101 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effective treatment of ureteral disorders: A Synthesis of Findings from 101 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to Dataset
Please check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key research findings

These studies show that various approaches are being attempted for the treatment of ulcerative colitis. For example, the study 34 shows that adjusting the dosage of the drug mesalamine could improve the symptoms of mild to moderate ulcerative colitis.

The study 5 indicates that the drug levamisole is ineffective in treating ulcerative colitis. On the other hand, the study 80 suggests that using probiotics such as bifid triple viable (BTV) in combination with aminosalicylic acid could improve ulcerative colitis symptoms and reduce side effects.

These studies suggest that dietary therapy and lifestyle improvements are also important factors in the treatment of ulcerative colitis, in addition to drug therapy.

treatment summary

The study 34 indicates that adjusting the dosage of the drug mesalamine could improve the symptoms of mild to moderate ulcerative colitis. The study compared two dosages of delayed-release oral mesalamine: 4.8 g/day (800 mg tablets) and 2.4 g/day (400 mg tablets). Results showed that the 4.8 g/day dosage was more effective than the 2.4 g/day dosage.

The study 5 shows that the drug levamisole is ineffective in treating ulcerative colitis. This study was a 2-year double-blind trial involving 50 patients, and it found that levamisole was ineffective in maintaining remission of ulcerative colitis.

The study 80 suggests that using probiotics such as bifid triple viable (BTV) in combination with aminosalicylic acid could improve ulcerative colitis symptoms and reduce side effects. This study was a systematic review and meta-analysis of treatments for ulcerative colitis using BTV combined with aminosalicylic acid. It found that BTV could potentially reduce drug-induced adverse reactions and have a good clinical effect on ulcerative colitis.

Benefits and Risks

Benefit Summary

These studies suggest that drugs such as mesalamine and probiotics could be effective in treating ulcerative colitis. Adjusting the dosage of mesalamine could also potentially improve symptoms more effectively. Additionally, using probiotics in combination with mesalamine could potentially reduce mesalamine side effects.

Risk Summary

Drugs such as mesalamine can have potential side effects. These can include vomiting, nausea, rash, diarrhea, and headaches. There is also the risk of side effects when using probiotics. To avoid these side effects, consult a doctor and receive appropriate treatment.

Research Comparison

Research Commonalities

All of these studies are related to the treatment of ulcerative colitis. They also research treatment methods such as drug therapy and probiotic therapy.

Research Differences

These studies vary in their target disease severity, treatment methods, and research designs. Therefore, it is not possible to directly compare the research findings.

Consistency and Contradictions in Results

These studies have shown some drugs and treatment methods that are effective in treating ulcerative colitis. However, not all research findings are consistent. For example, the study 5 shows that levamisole is ineffective, while other studies show that it is effective. Therefore, it is important to choose the most suitable treatment method for each individual patient with ulcerative colitis.

Considerations for Real-World Application

It is important to seek medical attention when treating ulcerative colitis. Refer to these research findings and discuss with your doctor to choose the best treatment method for you. Also, if you are using medication, be sure to discuss the risk of side effects with your doctor.

Limitations of Current Research

All of these studies are small-scale research. Therefore, the results of these studies cannot be generalized to all ulcerative colitis patients. Additionally, these studies have not investigated the long-term effects of specific treatment methods. Furthermore, the indicators used to evaluate the effectiveness of treatment methods differ in these studies. Therefore, it is not possible to directly compare the research findings.

Future Research Directions

More research on the treatment of ulcerative colitis is necessary. Long-term effects, comparisons of different treatment methods, and development of new treatment methods are particularly important. Additionally, these studies have a small number of participants, so larger-scale studies are needed.

Conclusion

Various approaches are being attempted for the treatment of ulcerative colitis. These studies suggest that drugs such as mesalamine and probiotics could be effective. However, not all research findings are consistent. Therefore, it is important to choose the most suitable treatment method for each individual patient. Consult with your doctor to choose the best treatment method for you.

List of Treatments

Mesalamine, levamisole, bifid triple viable, probiotics, dietary therapy, lifestyle improvements, corticosteroids, cyclosporine, infliximab, azathioprine, tacrolimus, methotrexate, beclomethasone dipropionate, nicotine, fecal microbiota transplantation, golimumab, guselkumab


Keywords
Benefit Keywords
Risk Keywords
Literature analysis of 101 papers
Positive Content
94
Neutral Content
1
Negative Content
6
Article Type
52
31
43
26
101

Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Author: IngramJohn R, ThomasGareth A O, RhodesJohn, GreenJohn T, HawkesNeil D, SwiftJill L, SrivastavaEmmanuel D, EvansBrian K, WilliamsGeraint T, NewcombeRobert G, CourtneyEdward, PillaiSuresh


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : German


Language : English


Language : English


Language : Spanish


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Author: CarbonnelFranck, ColombelJean Frédéric, FilippiJérome, KatsanosKonstantinos H, Peyrin-BirouletLaurent, AllezMathieu, NachuryMaria, NovacekGottfried, DaneseSilvio, AbitbolVered, BossaFabrizio, MoreauJacques, BommelaerGilles, BourreilleArnaud, FumeryMathurin, RoblinXavier, ReinischWalter, BouhnikYoram, BrixiHedia, SeksikPhilippe, MalamutGeorgia, FärkkiläMartti, CoulibalyBaya, DewitOlivier, LouisEdouard, DeplanqueDominique, MichettiPierre, SarterHélène, LaharieDavid,


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : Spanish


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.